Precision BioSciences receives patent allowances for HBV gene editing program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
March 11, 2026 7:01 AM EDTDURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Companys PBGENE-HBV program.
The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, titled Engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome. The 136... More
